Stockreport

NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

Neuraxis, Inc.  (NRXS) 
PDF Achieves significant expansion of NeurAxis’ total addressable marketClearance now includes patients aged “8 years and older”Expanded age indication will utilize the upco [Read more]